1.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-G000-303, NCT01321554
2.	Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-J081-202, NCT00946153
3.	E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-702, NCT01133977
4.	Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-G000-201, NCT00784303
5.	Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-G000-204, NCT01111461
6.	An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-G000-206, NCT01136967
7.	A Study in Subjects With Recurrent Malignant Glioma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-G000-203, NCT01137604
8.	A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-703, 2011-002347-10, NCT01529112
9.	A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-A001-102, NCT00121680
10.	An Open Label Phase I Dose Escalation Study Of E7080 Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-E044-101, NCT00121719
11.	An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-J081-103, NCT00280397
12.	E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-J081-110, NCT00832819
13.	A Study of E7080 in Subjects With Solid Tumor Phase: Phase I Type: Treatment Status: Closed Age: 18 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: E7080-J081-105, NCT01268293